Tumorvakzinierung – therapeutische Vakzinierung gegen Krebs
Standard
Tumorvakzinierung – therapeutische Vakzinierung gegen Krebs. / Rammensee, H-G; Löffler, M W; Walz, J S; Bokemeyer, C; Haen, S P; Gouttefangeas, C.
In: INTERNIST, Vol. 61, No. 7, 07.2020, p. 690-698.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Tumorvakzinierung – therapeutische Vakzinierung gegen Krebs
AU - Rammensee, H-G
AU - Löffler, M W
AU - Walz, J S
AU - Bokemeyer, C
AU - Haen, S P
AU - Gouttefangeas, C
PY - 2020/7
Y1 - 2020/7
N2 - Tumor cells always exhibit differences to normal cells. These differences can be recognized by the immune system, enabling the destruction of tumor cells by T cells, as was impressively demonstrated by the success of immune checkpoint inhibition, e.g., in malignant melanoma. Many cancers, however, do not respond to this kind of therapy. In these cases, vaccination against tumor antigens could be very helpful. Nevertheless, all of the efforts made in this respect during the past 30 years have been virtually futile. With current knowledge and technology there is new hope.
AB - Tumor cells always exhibit differences to normal cells. These differences can be recognized by the immune system, enabling the destruction of tumor cells by T cells, as was impressively demonstrated by the success of immune checkpoint inhibition, e.g., in malignant melanoma. Many cancers, however, do not respond to this kind of therapy. In these cases, vaccination against tumor antigens could be very helpful. Nevertheless, all of the efforts made in this respect during the past 30 years have been virtually futile. With current knowledge and technology there is new hope.
U2 - 10.1007/s00108-020-00814-z
DO - 10.1007/s00108-020-00814-z
M3 - SCORING: Review
C2 - 32462251
VL - 61
SP - 690
EP - 698
JO - INTERNIST
JF - INTERNIST
SN - 0020-9554
IS - 7
ER -
